HOME >> MEDICINE >> NEWS
Wilmington chemist wins national award for drug development

Chemist Paul S. Anderson of Lansdale, Pa., will be honored April 3 by the world's largest scientific society for directing the development of such drugs as Zocor for high cholesterol, Trusopt for glaucoma, and Crixivan and Sustiva for HIV. He will receive the 2001 Award in Industrial Chemistry from the American Chemical Society at its 221st national meeting in San Diego.

In a career that has involved shepherding Merck and DuPont pharmaceuticals from laboratory to market, Anderson concludes it's "a strong sense of community values" that makes the difference in drug discovery.

"That's what makes teams of researchers thrive," explained Anderson, the senior vice president of chemical and physical sciences at DuPont Pharmaceuticals Co. "You know somewhere in that sea of possibilities there is an answer. It comes when different people make little discoveries, share information, and work together to add it all up."

The discoveries of Crixivan and Sustiva, drugs that attack human immunodeficiency virus, each required the teamwork of over 100 experts, Anderson said from his Wilmington, Del., office.

"Both discovery processes were incredibly frustrating. Some molecules we made weren't soluble enough, others not potent enough, broke down too rapidly or couldn't get blood levels high enough to really attack HIV," he said.

Each project team tried and discarded about 1,000 drug candidates before Crixivan, a protease inhibitor, and Sustiva, a reverse transcriptase inhibitor, made it to market in 1996 and 1998, respectively.

Himself a medicinal chemist, Anderson said the project groups he directs are now developing the second generation of AIDS-fighting drugs. One is in Phase I and another in Phase II clinical trials.

Anderson said it was his father, a school superintendent, who sparked his career interest: "I remember we used to do kitchen-sink experiments at home while I was still in grade school," he said. "It got me really comfort
'"/>

Contact: Rodney Pearson
r_pearson@acs.org
202-872-4400
American Chemical Society
25-Mar-2001


Page: 1 2

Related medicine news :

1. NJIT chemistry professor edits text outlining best laboratory practices
2. Changing chemistry helps explain estrogen threat to the heart
3. Sealing corneal incisions with a drop of chemistry, BU researchers develop gel for cataract surgery
4. Herbal supplements testing topic of discussion at chemistry meeting March 30
5. Hopkins Peter Agre receives 2003 Nobel Prize in chemistry
6. Three Abbott chemists honored as Heroes for development of HIV therapy for children
7. Oregon State chemist wins national award for synthesizing molecules in nature
8. Chicago chemist wins national award for insights into how cells communicate
9. Irvine chemist wins national award for new drug techniques
10. Chicago chemist wins national award for new ways to make drug candidates
11. Illinois chemist wins national award for new drug research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Wilmington chemist wins national award for drug development

(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: